Gland Pharma Limited has announced the appointment of Mr. Xiao Le as the Chief Investment Officer for its wholly-owned subsidiary, Gland Pharma International Pte. Ltd. (Gland Singapore), effective November 09, 2026. Mr. Le will be instrumental in identifying and exploring investment opportunities, particularly enhancing M&A capabilities within the United States, China, Singapore, and other global markets. He brings over 15 years of extensive experience in investment and asset management across the biopharma and healthcare sectors.
Key Executive Appointment
Gland Pharma Limited announced today the appointment of Mr. Xiao Le to the significant role of Chief Investment Officer. This appointment is for its wholly-owned subsidiary, Gland Pharma International Pte. Ltd., referred to as ‘Gland Singapore’. The effective date for this new role is November 09, 2026.
Strategic Responsibilities
In his capacity as Chief Investment Officer, Mr. Xiao Le will lead the charge in exploring diverse investment avenues and bolstering the company’s Merger and Acquisition (M&A) capabilities. His strategic focus will be on key international markets, including the United States of America, China, and Singapore. Mr. Le will report directly to the CEO of Gland Singapore, aiming to drive growth and expand Gland Pharma’s global footprint through strategic investments.
Executive Profile and Experience
Mr. Xiao Le possesses a robust professional background with over 15 years of experience in investment and asset management. His expertise spans critical sectors such as medical devices, biopharma, diagnostics tools, and healthcare services. Prior to this appointment, he held notable positions including Chief Financial Officer at MegaRobo Technologies, Director on the Board of CANbridge Pharmaceuticals, and Senior Director of M&A and Strategic Investments at Wuxi AppTec. He has also served in various capacities at Dimensions Capital, Middleton Gardiner Group, LLC, NYSE, and Bank of America Merrill Lynch. Mr. Le holds a Bachelor’s degree in Bio-engineering from The Johns Hopkins University and a Master’s degree in Finance from The Massachusetts Institute of Technology, underscoring his strong academic and professional foundation.
Source: BSE
